Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England.
Kenrick NgPeter WilsonKatherine MutsvangwaLuke HounsomeJonathan ShamashPublished in: Prostate cancer and prostatic diseases (2021)
Black men may do better than white men with mCRPC, in the context of equal access to healthcare. The study also suggests a greater margin of benefit of hormone-based therapy in the black subpopulation.